Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
D

Protocol

MIND diet for preventing cognitive decline

In a 3-year trial of 604 older adults at risk of dementia, the MIND diet (a blend of Mediterranean and DASH eating focused on leafy greens, berries, nuts and olive oil) did not improve cognition more than a control diet; both groups also cut calories slightly.

Grade D, tested: a human randomized trial looked for a benefit on the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded and did not find one. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

The MIND diet blends Mediterranean and DASH eating, with leafy greens, berries, nuts and olive oil. In a three-year trial, older adults on the MIND diet did no better on thinking tests than people on a comparison diet. Both groups ate slightly fewer calories and both improved a little. Brain scans did not differ.

The letter, taken apart
What was measured
Thinking and memory test scores over 3 years.
How big
No difference in cognition between the diets (mean difference 0.035).Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 37466280.
Who it applies to
Adults aged 65 or older with overweight and a less healthy diet.
Safety
None identified.
The record in one view
Compared with
A control diet with the same mild calorie cut.
Certainty
Grade D, resting on: One 3-year randomized trial, primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. not met.
What would change this grade
Could rise to C with: Randomized trial of the MIND diet. Who: Older adults at risk of dementia. Measured: Dementia incidence. Length: At least 5 years.
Cost
No price recorded yet.
Sources
1 study cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
DMeasured function · Tested, no benefit Grade D

In a 3-year trial of 604 older adults at risk of dementia, the MIND diet (a blend of Mediterranean and DASH eating focused on leafy greens, berries, nuts and olive oil) did not improve cognition more than a control diet; both groups also cut calories slightly. Brain MRI measures did not differ either.

Why this letter

Why this gradeGrade D, tested, no benefit. The reasoning, and what the grade does not cover.
Why this grade

Grade D on Route 2 Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale. for cognitive decline. A 3-year randomized trial tested the MIND diet against a control diet and found no difference in cognition or brain MRI measures (Barnes et al., 2023; PMID 37466280).

WHAT THIS GRADE DOES NOT COVERthe Mediterranean diet, graded on its own record; dementia incidence, which a 3-year trial was too short to test; and people without overweight or with an already healthy diet, who were not enrolled.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial

Endpoint graded: Global cognition (functional)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of the MIND diet
PopulationOlder adults at risk of dementia
EndpointDementia incidence
DurationAt least 5 years

A positive trial of this shape would move this entry to C.

Why the current trials fall short

A longer trial measuring dementia could change the answer.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Diet, Mediterranean among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Diet, Mediterranean on ClinicalTrials.gov

Dose, form and timing

What to track

None; the trial found no difference.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 471 · November 2026 · First graded.
Grade history
No. 471 · November 2026 · First graded
MIND diet for preventing cognitive decline is added from the gap report: Grade D

New record in the gap-report batch. In a 3-year trial of 604 older adults at risk of dementia, the MIND diet (a blend of Mediterranean and DASH eating focused on leafy greens, berries, nuts and olive oil) did not improve cognition more than a control diet; both groups also cut calories slightly. Brain MRI measures did not differ either.PMID 37466280

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullOne paper, linked to its PubMed record.
The evidence

Barnes et al. (N Engl J Med, 2023; PMID 37466280): randomized trial, 604 adults aged 65 or older with overweight and a suboptimal diet, MIND diet with mild caloric restriction against a control diet with mild caloric restriction, 3 years; global cognition improved in both groups (mean difference 0.035, 95% CI -0.022 to 0.092); no differences in MRI measures.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 8 records screened, 1 eligible for the graded claim.
Query: ("MIND diet"[tiab]) AND randomized controlled trial[pt]
The 8 most recent of 20 records were screened by title; they are secondary analyses of the 2023 trial (PMID 37466280) or small trials of other outcomes.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Barnes et al., 2023, N Engl J Med (PMID 37466280): PubMed lists funding from National Institute on Aging; US National Institutes of Health (National Institute on Aging).

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026